Sona Nanotech Inc C.SONA

Alternate Symbol(s): SNANF

Technology Scientific & Technical Instruments

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.

CSE:SONA - Post by User

Sona Nanotech Inc > new game in town

<< Previous

Bullboard Posts

Next >>

Comment by Kaiseron Jun 17, 2021 11:27am

78 Views

Post# 33404374

RE:RE:RE:new game in town

Sona had better lab results then zen and look what happened. Depending on hc approval is a massive gamble. Ask the Sona share holders how that worked out. Zen is a bit too risky.

Specific wrote:

Pandora wrote:

Specific wrote: https://ceo.ca/@accesswire/zen-graphene-solutions-announces-exclusive-worldwide

Sometimes it seems you just get on the wrong horse. These guys were chasing face mask technology with graphene, now they have a saliva test, while Sona 15 months later is looking for a new product to bring life back into their business.

GUELPH, ON / ACCESSWIRE / June 17, 2021 / ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian, next-gen nanomaterials technology company, is pleased to announce that it has signed an exclusive agreement with McMaster University to be the global commercializing partner for a newly developed aptamer-based, SARS-CoV-2 rapid detection technology, developed by a team of researchers under the guidance of Drs. Yingfu Li, John Brennan and Leyla Soleymani, who are recognized as global leaders in biosensing technologies, and their applications as point of care (POC) diagnostics. This patent-pending technology is validated with clinical samples from patients recruited under the supervision of two clinicians, Drs. Deborah Yamamura and Bruno Salena, who also work at McMaster University. The project was funded by the Canadian Institutes of Health Research (CIHR). This technology is exceptionally accurate (similar to current PCR tests), saliva-based, affordable, scalable and provides results in under 10 minutes.

HC approval for their mask coating is expected by next thursday

https://stockhouse.com/news/press-releases/2021/06/16/zen-graphene-solutions-and-trebor-rx-provides-update